78 results on '"D'ANNA, BARBARA"'
Search Results
2. Factors Associated with Leg Ulcers in Adults with Sickle Cell Disease in Brazil
- Author
-
Valquíria Reis de Souza, Shannon Kelly, Ester Cerdeira Sabino, Franciane Mendes de Oliveira, Tassila Silva, Carolina Miranda Teixeira, Claudia Máximo, Paula Loureiro, Anna Barbara de Freitas Carneiro-Proietti, Isabel Gomes, Brian Custer, and Cesar de Almeida-Neto
- Subjects
Advanced and Specialized Nursing ,Dermatology - Published
- 2023
3. Contribution of Etiologic Cofactors to CIN3+ Risk Among Women With Human Papillomavirus–Positive Screening Test Results
- Author
-
Demarco, Maria, primary, Egemen, Didem, additional, Hyun, Noorie, additional, Chen, Xiaojian, additional, Moscicki, Anna-Barbara, additional, Cheung, Li, additional, Carter-Pokras, Olivia, additional, Hammer, Anne, additional, Gage, Julia C., additional, Clarke, Megan A., additional, Castle, Philip E., additional, Befano, Brian, additional, Chen, Jie, additional, Dallal, Cher, additional, He, Xin, additional, Desai, Kanan, additional, Lorey, Thomas, additional, Poitras, Nancy, additional, Raine-Bennett, Tina R., additional, Perkins, Rebecca B., additional, Wentzensen, Nicolas, additional, and Schiffman, Mark, additional
- Published
- 2022
- Full Text
- View/download PDF
4. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
- Author
-
Jane J. Kim, Richard S. Guido, David Chelmow, Ritu Nayar, Mark H. Einstein, Mark Schiffman, Nicolas Wentzensen, Philip E. Castle, Warner K. Huh, Rebecca B. Perkins, Anna-Barbara Moscicki, Francisco A.R. Garcia, George F. Sawaya, and Mona Saraiya
- Subjects
Colposcopy ,medicine.medical_specialty ,medicine.diagnostic_test ,Obstetrics ,business.industry ,Medical record ,HPV infection ,Obstetrics and Gynecology ,General Medicine ,Guideline ,medicine.disease ,Squamous intraepithelial lesion ,Risk Estimate ,Colposcopic Biopsy ,medicine ,business ,Risk assessment - Abstract
This is the fourth American Society of Colposcopy and Cervical Pathology (ASCCP)-sponsored consensus guidelines for management of cervical cancer screening abnormalities, after the original consensus conferences in 20011 and subsequent updates in 20062 and 2012.3 An interim guidance publication providing management recommendations for primary HPV screening was released in 2015.4 This document updates and replaces all previous guidance. The key difference between 2019 guidelines and previous versions is the change from primarily test results–based algorithms (e.g., “Colposcopy is recommended for patients with HPV-positive atypical squamous cells of undetermined significance [ASC-US], low-grade squamous intraepithelial lesion [LSIL],” etc.) to primarily “risk-based” guidelines (e.g., “Colposcopy is recommended for any combination of history and current test results yielding a 4.0% or greater probability of finding CIN 3+,” etc.). See Box 1 for essential changes. Tables of risk estimates for possible combinations of current screening test results and screening history (including unknown history) have been generated from a prospective longitudinal cohort of more than 1.5 million patients followed for more than a decade at Kaiser Permanente Northern California (KPNC). All KPNC estimates of risk underlying guideline decisions are detailed in the accompanying article by Egemen et al.5 The applicability of these risk estimates to other United States regions and populations has been confirmed in other data sets from screening programs and clinical trials.6 Many patients, especially those with minor abnormalities, can be managed by identifying their risk level using Tables 1A to 5B in Egemen et al5 and linking it to a recommended clinical action (return to routine screening, surveillance with repeat testing at 1- or 3-year intervals, colposcopy, or treatment). To facilitate use of these tables, the same information will be accessible via smartphone app (for purchase) and web (no cost) through http://www.asccp.org. Decision aids may facilitate use of the tables.7 Common abnormalities are managed using risk estimates outlined in Section E, and rare abnormalities are managed via the result-specific consensus recommendations outlined in Sections G-K. Box 1. Essential Changes From Prior Management Guidelines 1) Recommendations are based on risk, not results. Recommendations of colposcopy, treatment, or surveillance will be based on a patient's risk of CIN 3+ determined by a combination of current results and history (including unknown history). The same current test results may yield different management recommendations depending on the history of recent past test results. 2) Colposcopy can be deferred for certain patients. Repeat HPV testing or cotesting at 1 year is recommended for patients with minor screening abnormalities indicating HPV infection with low risk of underlying CIN 3+ (e.g., low-grade cytologic abnormalities after a documented negative screening HPV test or cotest). At the 1-year follow-up test, referral to colposcopy is recommended if results remain abnormal. 3) Guidance for expedited treatment is expanded (i.e., treatment without colposcopic biopsy). Expedited treatment was an option for patients with HSIL cytology in the 2012 guidelines; this guidance is now better defined. For nonpregnant patients 25 years or older, expedited treatment, defined as treatment without preceding colposcopic biopsy demonstrating CIN 2+, is preferred when the immediate risk of CIN 3+ is ≥60%, and is acceptable for those with risks between 25% and 60%. Expedited treatment is preferred for nonpregnant patients 25 years or older with high-grade squamous intraepithelial lesion (HSIL) cytology and concurrent positive testing for HPV genotype 16 (HPV 16) (i.e., HPV 16–positive HSIL cytology) and never or rarely screened patients with HPV-positive HSIL regardless of HPV genotype. Shared decision-making should be used when considering expedited treatment, especially for patients with concerns about the potential impact of treatment on pregnancy outcomes. 4) Excisional treatment is preferred to ablative treatment for histologic HSIL (CIN 2 or CIN 3) in the United States. Excision is recommended for adenocarcinoma in situ (AIS). 5) Observation is preferred to treatment for CIN 1. Treatment remains acceptable for patients with repeat diagnoses of CIN 1 persisting 2 years or more. 6) Histopathology reports based on Lower Anogenital Squamous Terminology (LAST)/World Health Organization (WHO) recommendations for reporting histologic HSIL should include CIN 2 or CIN 3 qualifiers, i.e., HSIL(CIN 2) and HSIL (CIN 3). 7) All positive HPV tests, regardless of genotype, should have additional reflex triage testing performed from the same laboratory specimen (e.g., reflex cytology). Additional testing from the same laboratory specimen is recommended because the findings may inform colposcopy practice. For example, those with HSIL cytology and concurrent positive testing for HPV genotype 16 qualify for expedited treatment. HPV 16 or 18 infections have the highest risk for CIN 3 and occult cancer, so additional evaluation (e.g., colposcopy with biopsy) is necessary even when cytology results are negative. If HPV 16 and 18 testing is positive, and additional laboratory testing of the same sample is not feasible, the patient should proceed directly to colposcopy. 8) Continued surveillance with HPV testing or cotesting at 3-year intervals for at least 25 years is recommended after treatment of histologic HSIL, CIN 2, CIN 3, or AIS. Continued surveillance at 3-year intervals beyond 25 years is acceptable for as long as the patient's life expectancy and ability to be screened are not significantly compromised by serious health issues. The 2012 guidelines recommended return to 5-year screening intervals and did not specify when screening should cease. New evidence indicates that risk remains elevated for at least 25 years, with no evidence that treated patients ever return to risk levels compatible with 5-year intervals. Surveillance with cytology alone is acceptable only if testing with HPV or cotesting is not feasible. Cytology is less sensitive than HPV testing for detection of precancer and is therefore recommended more often. Cytology is recommended at 6-month intervals when HPV testing or cotesting is recommended annually. Cytology is recommended annually when 3-year intervals are recommended for HPV or cotesting. 9) Human papilloma virus assays that are Food and Drug Administration (FDA)-approved for screening should be used for management according to their regulatory approval in the United States. (Note: all HPV testing in this document refers to testing for high-risk HPV types only). For all management indications, HPV mRNA and HPV DNA tests without FDA approval for primary screening alone should only be used as a cotest with cytology, unless sufficient, exceptionally rigorous data are available to support primary HPV testing in management. The minimum amount of data required to generate a recommendation will include the patient's age and current test results, as we recognize that previous screening history is often not known. Increased precision of management guidance will be possible if information is available on test results within the past 5 years and previous precancer treatment within the past 25 years.3 Current results and past history are designed to generate the patient's risk estimate from data tables.5 Risk estimates are available for the following clinical situations: abnormal screening test results with unknown history, abnormal screening test results with medical record documentation of a preceding negative HPV test or cotest, surveillance of previous abnormal screening test results that did not require immediate colposcopic referral (e.g., follow-up after an HPV-positive cytology negative result), colposcopy/biopsy results, and follow-up surveillance tests after colposcopy or after treatment for, or resolution of, high-grade abnormalities (e.g., CIN 2+). The recognition that persistent HPV infection is necessary for developing precancer and cancer (defined as CIN 3+, which includes diagnoses of CIN 3, AIS, and cancer) underlies the 2019 guideline update. Prospective longitudinal data indicate that when a new abnormal screening test result follows a negative HPV test or cotest within the past 5 years, the estimated risk of CIN 3+ is reduced by approximately 50%.8 A negative cytology result within 3 years of a new abnormal screening test, however, does not confer a similar reduction in risk.9 The 2019 guidelines also recognize that a colposcopic examination performed according to accepted standards (e.g., using the KPNC colposcopy protocol or the ASCCP Colposcopy Standards10) confirming low-grade or normal histology reduces a patient's estimated risk of having precancer/cancer in the next 2 years.11 This allows patients with an HPV-positive ASC-US or LSIL result at their 1-year follow-up visit after a colposcopy confirming normal- or low-grade histology to return for repeat HPV or cotesting in 1 more year, rather than immediately return to colposcopy. Thus, incorporating a patient's history of previous HPV tests and colposcopy/biopsy results will permit detection and treatment of CIN 3+ while avoiding unnecessary interventions for patients with new HPV infections who are at lower risk.12
- Published
- 2020
5. The association between oral disease and type of antiretroviral therapy among perinatally HIV-infected youth
- Author
-
George R. Seage, Tzy-Jyun Yao, Jonathan S Russell, Mark I. Ryder, Anna-Barbara Moscicki, Caroline H. Shiboski, and Russell B. Van Dyke
- Subjects
Male ,Cart ,medicine.medical_specialty ,Adolescent ,Cross-sectional study ,Immunology ,Bleeding on probing ,Integrase inhibitor ,HIV Infections ,Article ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Antiretroviral Therapy, Highly Active ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Young adult ,Periodontal Diseases ,business.industry ,Stomatognathic Diseases ,030206 dentistry ,Viral Load ,medicine.disease ,CD4 Lymphocyte Count ,stomatognathic diseases ,Cross-Sectional Studies ,Infectious Diseases ,Anti-Retroviral Agents ,Female ,medicine.symptom ,business ,Viral load ,Cohort study - Abstract
Objectives This study explores the association between combination antiretroviral therapy (cART) and oral health outcomes (dental and periodontal) among perinatally HIV-infected (PHIV) youth. Methods We conducted a cross-sectional study of oral health among PHIV youth participating in the Oral Health substudy of the Pediatric HIV/AIDS Cohort Study (PHACS). Dentists at research sites were trained/calibrated on how to perform a standardized oral mucosal, dental and periodontal examination. They assessed the decayed-missing-filled-surfaces and teeth index (DMFS/T). The number of decayed surfaces and teeth and the number of teeth with gingival bleeding on probing for each participant were derived from the examination. Data for analysis included lifetime measurements of CD4 cell count and viral load, sociodemographic information and current/past history of ART. Results Among 209 PHIV youth, 95% were on ART at the time of enrolment. Among 143 PHIV youth on the same cART for at least 1 year, we found that the mean decayed teeth score of those receiving cART containing an integrase inhibitor was 86% higher than that of those on cART without an integrase inhibitor after adjusting for age, lifetime proportion of unsuppressed viral load and CD4 cell count nadir. Initiating protease inhibitors before age 6 years was associated with a significantly lower DMFT score than participants who initiated at age 6 years and older. Conclusion Our study revealed that PHIV youth who received cART containing an integrase inhibitor had a significantly higher number of untreated active caries than those on cART without an integrase inhibitor. This may warrant closer dental surveillance of those receiving an integrase inhibitor.
- Published
- 2018
6. Should Cervical Cancer Screening be Performed Before the Age of 25 Years?
- Author
-
Rebecca B. Perkins, Anna-Barbara Moscicki, Marion Saville, and Julia M.L. Brotherton
- Subjects
Adult ,medicine.medical_specialty ,MEDLINE ,Uterine Cervical Neoplasms ,Cervical cancer screening ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Health care ,medicine ,Health insurance ,Humans ,030212 general & internal medicine ,Young adult ,Early Detection of Cancer ,Cervical cancer ,Intraepithelial neoplasia ,Forum ,business.industry ,Obstetrics ,Age Factors ,Obstetrics and Gynecology ,General Medicine ,medicine.disease ,United States ,Vaccination ,030220 oncology & carcinogenesis ,Female ,business ,Facilities and Services Utilization - Abstract
When should young women begin cervical cancer screening? Dr. Moscicki states that we should continue to initiate screening before the age of 25 years in the US. The reasons include a lower rate of HPV vaccination among the current generation of young adult women and increases in invasive cervical cancer cases in countries that have raised the screening age to 25 years. She further cites specific shortcomings of the US healthcare system that can contribute to underscreening among young women, including fragmented healthcare, lack of health insurance, and a rapidly declining rate of pelvic examinations for cervical cancer screening among this age group, despite current guidelines that continue to recommend screening. She posits that although cervical cancer is rare among women aged 21 to 24 years, promoting screening in this age group acts as a safety net to prevent cancers among women aged 25 to 29 years.
- Published
- 2018
7. Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States
- Author
-
Mark Schiffman, Cara Mathews, Martha M. Mitchell, Warner K. Huh, Rebecca B. Perkins, Christine Conageski, Kim Choma, Michelle J. Khan, Elizabeth A. Stier, Mark H. Einstein, Theognosia Papasozomenos, Angela Liu, Edward J. Mayeaux, Richard S. Guido, Michael A. Gold, Akiva P. Novetsky, Barbara S. Apgar, Alan G. Waxman, Michelle I. Silver, Candice A. Tedeschi, Nicolas Wentzensen, Claudia L. Werner, Anna-Barbara Moscicki, L. Stewart Massad, Francisco A.R. Garcia, Julia C. Gage, Jose Jeronimo, David Chelmow, Teresa M. Darragh, and Katie M. Smith
- Subjects
medicine.medical_specialty ,Evidence-based practice ,cervical cancer ,Clinical Sciences ,MEDLINE ,Uterine Cervical Neoplasms ,Cervical cancer screening ,evidence based ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,biopsy ,Obstetrics & Reproductive Medicine ,Early Detection of Cancer ,Colposcopy ,Cervical cancer ,Cervical pathology ,Gynecology ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,business.industry ,screening ,colposcopy ,Obstetrics and Gynecology ,General Medicine ,medicine.disease ,United States ,030220 oncology & carcinogenesis ,Family medicine ,recommendations ,Cervical cancer prevention ,Female ,business - Abstract
The American Society for Colposcopy and Cervical Pathology (ASCCP) Colposcopy Standards recommendations address the role of colposcopy and directed biopsy for cervical cancer prevention in the United States (US). The recommendations were developed by an expert working group appointed by ASCCP's Board of Directors. An extensive literature review was conducted and supplemented by a systematic review and meta-analysis of unpublished data. In addition, a survey of practicing colposcopists was conducted to assess current colposcopy practice in the US. Recommendations were approved by the working group members, and the final revisions were made based on comments received from the public. The recommendations cover terminology, risk-based colposcopy, colposcopy procedures, and colposcopy adjuncts. The ASCCP Colposcopy Standards recommendations are an important step toward raising the standard of colposcopy services delivered to women in the US. Because cervical cancer screening programs are currently undergoing important changes that may affect colposcopy performance, updates to some of the current recommendations may be necessary in the future.
- Published
- 2017
8. Human Spheroids from Adipose-Derived Stem Cells Induce Calvarial Bone Production in a Xenogeneic Rabbit Model
- Author
-
Di Stefano, Anna Barbara, primary, Montesano, Luigi, additional, Belmonte, Beatrice, additional, Gulino, Alessandro, additional, Gagliardo, Cesare, additional, Florena, Ada Maria, additional, Bilello, Giuseppa, additional, Moschella, Francesco, additional, Cordova, Adriana, additional, Leto Barone, Angelo A., additional, and Toia, Francesca, additional
- Published
- 2020
- Full Text
- View/download PDF
9. Response to Letter to the Editor Regarding: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
- Author
-
Perkins, Rebecca B., primary, Guido, Richard L., additional, Castle, Philip E., additional, Chelmow, David, additional, Einstein, Mark H., additional, Garcia, Francisco, additional, Huh, Warner K., additional, Kim, Jane J., additional, Moscicki, Anna-Barbara, additional, Nayar, Ritu, additional, Saraiya, Mona, additional, Sawaya, George, additional, Wentzensen, Nicolas, additional, and Schiffman, Mark, additional
- Published
- 2020
- Full Text
- View/download PDF
10. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
- Author
-
Perkins, Rebecca B., primary, Guido, Richard S., additional, Castle, Philip E., additional, Chelmow, David, additional, Einstein, Mark H., additional, Garcia, Francisco, additional, Huh, Warner K., additional, Kim, Jane J., additional, Moscicki, Anna-Barbara, additional, Nayar, Ritu, additional, Saraiya, Mona, additional, Sawaya, George F., additional, Wentzensen, Nicolas, additional, and Schiffman, Mark, additional
- Published
- 2020
- Full Text
- View/download PDF
11. Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines
- Author
-
Warner K. Huh, Philip E. Castle, David Chelmow, Nicolas Wentzensen, Richard S. Guido, Mark Schiffman, Michelle J. Khan, Teresa M. Darragh, Colleen K. Stockdale, Michelle I. Silver, and Anna-Barbara Moscicki
- Subjects
Societies, Scientific ,medicine.medical_specialty ,030219 obstetrics & reproductive medicine ,Cervical screening ,business.industry ,Alternative medicine ,MEDLINE ,Disease Management ,Uterine Cervical Neoplasms ,Obstetrics and Gynecology ,General Medicine ,Article ,National Cancer Institute (U.S.) ,United States ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Family medicine ,Practice Guidelines as Topic ,medicine ,Humans ,Female ,Disease management (health) ,business ,Early Detection of Cancer - Published
- 2017
12. Response to Letter to the Editor Regarding: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
- Author
-
Jane J. Kim, Nicolas Wentzensen, Anna-Barbara Moscicki, Richard L. Guido, Mark Schiffman, Warner K. Huh, Rebecca B. Perkins, David Chelmow, Mark H. Einstein, Philip E. Castle, Ritu Nayar, Mona Saraiya, George F. Sawaya, and Francisco A.R. Garcia
- Subjects
Vaginal Smears ,Oncology ,medicine.medical_specialty ,Letter to the editor ,business.industry ,MEDLINE ,Uterine Cervical Neoplasms ,Obstetrics and Gynecology ,Cancer ,General Medicine ,Cervical cancer screening ,medicine.disease ,Colposcopy ,Pregnancy ,Internal medicine ,medicine ,Humans ,Female ,business ,Early Detection of Cancer - Published
- 2020
13. Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women
- Author
-
El-Zein, Mariam, primary, Ramanakumar, Agnihotram V., additional, Naud, Paulo, additional, Roteli-Martins, Cecilia M., additional, de Carvalho, Newton S., additional, Colares de Borba, Paola, additional, Teixeira, Julio C., additional, Moscicki, Anna-Barbara, additional, Harper, Diane M., additional, Tyring, Stephen K., additional, Ramjattan, Brian, additional, Dubin, Gary, additional, and Franco, Eduardo L., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection
- Author
-
Moscicki, Anna-Barbara, primary, Flowers, Lisa, additional, Huchko, Megan J., additional, Long, Margaret E., additional, MacLaughlin, Kathy L., additional, Murphy, Jeanne, additional, Spiryda, Lisa Beth, additional, and Gold, Michael A., additional
- Published
- 2019
- Full Text
- View/download PDF
15. Immunomodulation in Vascularized Composite Allotransplantation
- Author
-
Pappalardo, Marco, primary, Montesano, Luigi, additional, Toia, Francesca, additional, Russo, Antonio, additional, Di Lorenzo, Sara, additional, Dieli, Francesco, additional, Moschella, Francesco, additional, Leto Barone, Angelo A., additional, Meraviglia, Serena, additional, and Di Stefano, Anna Barbara, additional
- Published
- 2019
- Full Text
- View/download PDF
16. The association between oral disease and type of antiretroviral therapy among perinatally HIV-infected youth
- Author
-
Shiboski, Caroline H., primary, Yao, Tzy-Jyun, additional, Russell, Jonathan S., additional, Ryder, Mark I., additional, Van Dyke, Russell B., additional, Seage, George R., additional, and Moscicki, Anna-Barbara, additional
- Published
- 2018
- Full Text
- View/download PDF
17. Should Cervical Cancer Screening be Performed Before the Age of 25 Years?
- Author
-
Moscicki, Anna-Barbara, primary, Perkins, Rebecca B., additional, Saville, Marion, additional, and Brotherton, Julia M. L., additional
- Published
- 2018
- Full Text
- View/download PDF
18. Oral Human Papillomavirus in Youth From the Pediatric HIV/AIDS Cohort Study
- Author
-
Rohan Hazra, Sepideh Farhat, Tzy-Jyun Yao, Van Dyke Rb, Russell Js, Caroline H. Shiboski, Mark I. Ryder, and Anna-Barbara Moscicki
- Subjects
Male ,Microbiology (medical) ,medicine.medical_specialty ,Adolescent ,Genotype ,Pediatric hiv ,Cross-sectional study ,HIV Infections ,Dermatology ,California ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,Humans ,Medicine ,030212 general & internal medicine ,Papillomaviridae ,Human papillomavirus ,Acquired Immunodeficiency Syndrome ,biology ,Coinfection ,business.industry ,Papillomavirus Infections ,Public Health, Environmental and Occupational Health ,virus diseases ,Viral Load ,biology.organism_classification ,medicine.disease ,CD4 Lymphocyte Count ,Cross-Sectional Studies ,Infectious Diseases ,030220 oncology & carcinogenesis ,Female ,Mouth Diseases ,business ,Viral load ,Cohort study - Abstract
In contrast to high rates of oral human papillomavirus (HPV) found in human immunodeficiency virus (HIV)-infected adults, only 2% of 209 perinatally HIV-infected youth had oral HPV. This rate was similar in HIV-exposed but uninfected youth. No association was found with sexual activity; however, low CD4 counts were associated with oral HPV.
- Published
- 2016
19. PD37-08 ENHANCING THE EFFICACY OF VALPROIC ACID IN PROSTATE CANCER CELLS WITH NUTRITIONAL SUPPLEMENTS
- Author
-
Daniel Oh, Ronald Rodriguez, Grace I. Todd, Anna-Barbara O'James, Mizanur Rahman, Jatindar Goyal, Wasim H. Chowdhury, and Abhinav Sidana
- Subjects
Valproic Acid ,Prostate cancer ,business.industry ,Urology ,medicine ,Pharmacology ,medicine.disease ,business ,medicine.drug - Published
- 2017
20. Trends in Cervical Cancer Screening in California's Family Planning Program
- Author
-
Thiel de Bocanegra, Heike, primary, Navarro, Sandy K., additional, Nonzee, Narissa J., additional, Vangala, Sitaram, additional, Zhou, Xinkai, additional, Chang, Charlene, additional, and Moscicki, Anna-Barbara, additional
- Published
- 2018
- Full Text
- View/download PDF
21. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children
- Author
-
Weinberg, Adriana, primary, Huang, Sharon, additional, Moscicki, Anna-Barbara, additional, Saah, Afred, additional, and Levin, Myron J., additional
- Published
- 2018
- Full Text
- View/download PDF
22. ASCCP Colposcopy Standards: Role of Colposcopy, Benefits, Potential Harms, and Terminology for Colposcopic Practice
- Author
-
Khan, Michelle J., primary, Werner, Claudia L., additional, Darragh, Teresa M., additional, Guido, Richard S., additional, Mathews, Cara, additional, Moscicki, Anna-Barbara, additional, Mitchell, Martha M., additional, Schiffman, Mark, additional, Wentzensen, Nicolas, additional, Massad, L. Stewart, additional, Mayeaux, E.J., additional, Waxman, Alan G., additional, Conageski, Christine, additional, Einstein, Mark H., additional, and Huh, Warner K., additional
- Published
- 2017
- Full Text
- View/download PDF
23. Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States
- Author
-
Wentzensen, Nicolas, primary, Massad, L. Stewart, additional, Mayeaux, Edward J., additional, Khan, Michelle J., additional, Waxman, Alan G., additional, Einstein, Mark H., additional, Conageski, Christine, additional, Schiffman, Mark H., additional, Gold, Michael A., additional, Apgar, Barbara S., additional, Chelmow, David, additional, Choma, Kim K., additional, Darragh, Teresa M., additional, Gage, Julia C., additional, Garcia, Francisco A.R., additional, Guido, Richard S., additional, Jeronimo, Jose A., additional, Liu, Angela, additional, Mathews, Cara A., additional, Mitchell, Martha M., additional, Moscicki, Anna-Barbara, additional, Novetsky, Akiva P., additional, Papasozomenos, Theognosia, additional, Perkins, Rebecca B., additional, Silver, Michelle I., additional, Smith, Katie M., additional, Stier, Elizabeth A., additional, Tedeschi, Candice A., additional, Werner, Claudia L., additional, and Huh, Warner K., additional
- Published
- 2017
- Full Text
- View/download PDF
24. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
- Author
-
Debbie, Saslow, Diane, Solomon, Herschel W, Lawson, Maureen, Killackey, Shalini L, Kulasingam, Joanna M, Cain, Francisco A R, Garcia, Ann T, Moriarty, Alan G, Waxman, David C, Wilbur, Nicolas, Wentzensen, Levi S, Downs, Mark, Spitzer, Anna-Barbara, Moscicki, Eduardo L, Franco, Mark H, Stoler, Mark, Schiffman, Philip E, Castle, Evan R, Myers, David, Chelmow, Abbe, Herzig, Jane J, Kim, Walter, Kinney, W Lawson, Herschel, and Jeffrey, Waldman
- Subjects
Uterine Cervical Neoplasms ,Mass Screening ,Papillomaviridae ,Societies, Medical ,Early Detection of Cancer ,American Cancer Society ,Cervical cancer ,Colposcopy ,Evidence-Based Medicine ,biology ,medicine.diagnostic_test ,Clinical pathology ,Biopsy, Needle ,Age Factors ,Obstetrics and Gynecology ,Hematology ,General Medicine ,Middle Aged ,Immunohistochemistry ,Oncology ,Practice Guidelines as Topic ,Female ,Adult ,medicine.medical_specialty ,Cytodiagnosis ,MEDLINE ,Early detection ,Cervical intraepithelial neoplasia ,Article ,Young Adult ,medicine ,Humans ,Mass screening ,Aged ,Vaginal Smears ,Gynecology ,Risk Management ,business.industry ,Papillomavirus Infections ,Cancer ,Guideline ,Evidence-based medicine ,biology.organism_classification ,Uterine Cervical Dysplasia ,medicine.disease ,United States ,Family medicine ,business - Abstract
An update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical precancerous lesions and cancer is presented. The guidelines are based on a systematic evidence review, contributions from 6 working groups, and a recent symposium cosponsored by the ACS, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology, which was attended by 25 organizations. The new screening recommendations address age-appropriate screening strategies, including the use of cytology and high-risk human papillomavirus (HPV) testing, follow-up (eg, the management of screen positives and screening intervals for screen negatives) of women after screening, the age at which to exit screening, future considerations regarding HPV testing alone as a primary screening approach, and screening strategies for women vaccinated against HPV16 and HPV18 infections. CA Cancer J Clin 2012;62:147-172. V C
- Published
- 2012
25. Cervical Ectopy and the Acquisition of Human Papillomavirus in Adolescents and Young Women
- Author
-
Sepideh Farhat, Yifei Ma, Loris Y. Hwang, Jay A. Lieberman, and Anna-Barbara Moscicki
- Subjects
medicine.medical_specialty ,Adolescent ,Cervix Uteri ,Cervical intraepithelial neoplasia ,Article ,Young Adult ,Risk Factors ,Prevalence ,medicine ,Humans ,Prospective Studies ,Young adult ,Prospective cohort study ,Gynecology ,business.industry ,Proportional hazards model ,Obstetrics ,Incidence ,Incidence (epidemiology) ,Papillomavirus Infections ,Hazard ratio ,Obstetrics and Gynecology ,medicine.disease ,Confidence interval ,Sexual Partners ,Menarche ,Female ,business - Abstract
OBJECTIVE: Higher rates of human papillomavirus (HPV) in adolescents and younger women have been attributed to their greater extent of “cervical ectopy,” defined as columnar and metaplastic epithelia on the ectocervix. Our objective was to estimate associations between ectopy and incident HPV in healthy adolescents and young women. METHODS: Enrolled between October 2000 and October 2002, this prospective cohort included women aged 13–21 years who were sexually active, without previous cervical intraepithelial neoplasia, cervical procedures, or immunosuppression, with menarche within 6 years before enrollment, and negative for HPV DNA at baseline. Every 4 months, extent of ectopy was quantitatively measured using colpophotography and computerized planimetry. Cox proportional hazards models examined associations between ectopy and incident HPV, defined as the first positive HPV result during follow-up. RESULTS: The 138 women attended 509 total visits. At baseline, mean age was 16.7 years and mean extent of ectopy was 25% of the total cervical face. Incident HPV of any type was detected in 42 (30%) women and was not significantly associated with baseline ectopy (hazard ratio 1.09, 95% confidence interval 0.96–1.25; P=.20; ectopy in units of 10%), or with ectopy measured 4 months before HPV detection (hazard ratio 1.09, confidence interval 0.94–1.26; P=.25). Our sample size had 80% power to detect a hazard ratio of 1.9 (with two-tailed α=0.05). Results were similarly insignificant for HPV subgroupings of incident high-risk, low-risk, α9, and α3/α15 types, and when adjusted for new sexual partners. CONCLUSION: Extent of cervical ectopy was not associated with HPV acquisition in healthy adolescents and young women. Biological vulnerabilities may lie in immune function or other characteristics of the cervical epithelium. LEVEL OF EVIDENCE: II
- Published
- 2012
26. Human Papillomavirus in Men
- Author
-
Joel M. Palefsky and Anna-Barbara Moscicki
- Subjects
Male ,medicine.medical_specialty ,Article ,Genital warts ,Risk Factors ,Humans ,Medicine ,Papillomavirus Vaccines ,Human papillomavirus ,Penile Neoplasms ,Gynecology ,Human papillomavirus 16 ,Human papillomavirus 18 ,business.industry ,Extramural ,Papillomavirus Infections ,virus diseases ,Obstetrics and Gynecology ,General Medicine ,Anus Neoplasms ,medicine.disease ,Dermatology ,Condylomata Acuminata ,Oral Cancers ,Mouth Neoplasms ,business - Abstract
HPV 6 and 11 cause greater than 90% of genital warts in males and females. Data show that approximately 3–4 million cases of genital warts in men occur each year with a peak rate of 500 per 100,000 in the 25–29 year old group. (1) The majority of these genital warts are diagnosed in men under the age of 30 years. In addition to genital warts, men are at risk for several HPV-related morbidities including penile, anal and oral cancers.
- Published
- 2011
27. Rate of and Risks for Regression of Cervical Intraepithelial Neoplasia 2 in Adolescents and Young Women
- Author
-
Adaleen Powers, Charles Wibbelsman, Teresa M. Darragh, Anna-Barbara Moscicki, Sepideh Farhat, Yifei Ma, and Stephen Shiboski
- Subjects
medicine.medical_specialty ,Adolescent ,Uterine Cervical Neoplasms ,Cervical intraepithelial neoplasia ,Article ,Young Adult ,medicine ,Humans ,Papillomaviridae ,Risk factor ,Young adult ,Prospective cohort study ,Gynecology ,Cervical cancer ,biology ,Obstetrics ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,Uterine Cervical Dysplasia ,medicine.disease ,biology.organism_classification ,female genital diseases and pregnancy complications ,Regression ,Natural history ,Neoplasm Regression, Spontaneous ,Disease Progression ,Female ,business - Abstract
To describe the natural history of cervical intraepithelial neoplasia (CIN) 2 in a prospective study of adolescents and young women, and to examine the behavioral and biologic factors associated with regression and progression.Adolescents and women aged 13 to 24 years who were referred for abnormal cytology and were found to have CIN 2 on histology were evaluated at 4-month intervals. Risks for regression were defined as three consecutive negative cytology and histology visits, and progression to CIN 3 was estimated using Cox proportional hazards regression models.Ninety-five patients with a mean age of 20.4 years (±2.3) were entered into the analysis. Thirty-eight percent resolved by year 1, 63% resolved by year 2, and 68% resolved by year 3. Multivariable analysis found that recent Neisseria gonorrhoeae infection (hazard ratio 25.27; 95% confidence interval [CI] 3.11-205.42) and medroxyprogesterone acetate use (per month) (hazard ratio 1.02; 95% CI 1.003-1.04) were associated with regression. Factors associated with nonregression included combined hormonal contraception use (per month) (hazard ratio 0.85; 95% CI 0.75-0.97) and persistence of human papillomavirus (HPV) of any type (hazard ratio 0.40; 95% CI 0.22-0.72). Fifteen percent of patients showed progression by year 3. HPV 16/18 persistence (hazard ratio 25.27; 95% CI 2.65-241.2; P=.005) and HPV 16/18 status at last visit (hazard ratio 7.25; 95% CI 1.07-49.36; P.05) were associated with progression Because of the small sample size, other covariates were not examined.The high regression rate of CIN 2 supports clinical observation of this lesion in adolescents and young women.
- Published
- 2010
28. Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa
- Author
-
Yifei Ma, Anu Rebbapragada, Stephen Shiboski, Craig R. Cohen, Rupert Kaul, Mark E. Scott, Ibrahim I. Daud, Joelle Brown, Elizabeth A. Bukusi, and Anna-Barbara Moscicki
- Subjects
Male ,Adolescent ,Cross-sectional study ,Immunology ,Population ,HIV Infections ,Cervix Uteri ,Biology ,Article ,Young Adult ,Immune system ,Risk Factors ,Immunity ,parasitic diseases ,medicine ,Humans ,Immunology and Allergy ,Secretory Leukocyte Peptidase Inhibitor ,Viral shedding ,Young adult ,education ,Immunity, Mucosal ,Cervix ,Africa South of the Sahara ,education.field_of_study ,Genitalia, Female ,United States ,Virus Shedding ,Cross-Sectional Studies ,Infectious Diseases ,medicine.anatomical_structure ,Mucosal immunology ,HIV-1 ,Female - Abstract
To determine whether healthy, young women in sub-Saharan Africa have a more activated immune milieu in the genital tract (i.e. activated CD4 T cells) than a similar population in the United States.A cross-sectional study nested in a phase 1 microbicide trial.Cervical cytobrushes were collected from 18 to 24-year-old women in San Francisco, California, USA (n = 18) and Kisumu, Kenya (n = 36) at enrollment into a phase 1 microbicide trial. All participants tested negative for HIV, herpes simplex virus 2, gonorrhea, chlamydia, and trichomonas, and had abstained from sex for at least 7 days prior to enrollment. Cryopreserved T-cell populations were assayed by flow cytometry in a central laboratory. Secretory leukocyte protease inhibitor levels were assayed in cervicovaginal lavage samples. The Wilcoxon rank-sum test was used to compare immune parameters between sites.The total number of endocervical CD4(+) T cells was slightly higher in participants from San Francisco, but participants from Kisumu had a substantially higher number and proportion of CD4(+) T cells expressing the early activation marker CD69, with and without the HIV coreceptor C-C chemokine receptor type 5, and a greater proportion of activated CD8(+) T cells. Median (interquartile range) genital levels of secretory leukocyte protease inhibitor were lower in participants from Kisumu compared with those from San Francisco [190 (96-519) vs. 474 (206 817) pg/ml, P0.03].Activated mucosal T cells were increased in the genital tract of young, sexually transmitted infection/HIV-free Kenyan women, independent of common genital coinfections, and secretory leukocyte protease inhibitor levels were reduced. The cause of these mucosal immune differences is not known, but could partly explain the high HIV incidence in young women from sub-Saharan Africa.
- Published
- 2010
29. Practice Improvement in Cervical Screening and Management (PICSM): Simposio sobre el manejo de las anomalías cervicales en adolescentes y mujeres jóvenes
- Author
-
Anna-Barbara Moscicki and Thomas J Cox
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,medicine ,Obstetrics and Gynecology ,General Medicine ,business - Published
- 2010
30. Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines
- Author
-
Schiffman, Mark, primary, Wentzensen, Nicolas, additional, Khan, Michelle J., additional, Castle, Philip E., additional, Chelmow, David, additional, Huh, Warner K., additional, Moscicki, Anna Barbara, additional, Stockdale, Colleen K., additional, Darragh, Teresa M., additional, Silver, Michelle, additional, and Guido, Richard S., additional
- Published
- 2017
- Full Text
- View/download PDF
31. PD37-08 ENHANCING THE EFFICACY OF VALPROIC ACID IN PROSTATE CANCER CELLS WITH NUTRITIONAL SUPPLEMENTS
- Author
-
Chowdhury, Wasim H., primary, O'James, Anna-Barbara, additional, Sidana, Abhinav, additional, Goyal, Jatindar, additional, Oh, Daniel, additional, Todd, Grace I., additional, Rahman, Mizanur, additional, and Rodriguez, Ronald, additional
- Published
- 2017
- Full Text
- View/download PDF
32. Cervical Cytology Testing in Teens
- Author
-
Anna-Barbara Moscicki
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Population ,Cytology ,medicine ,Humans ,Mass Screening ,DNA Probes, HPV ,education ,Cervix ,Papillomaviridae ,Mass screening ,Colposcopy ,Gynecology ,Cervical cancer ,education.field_of_study ,medicine.diagnostic_test ,Obstetrics ,business.industry ,Papillomavirus Infections ,Obstetrics and Gynecology ,Cancer ,medicine.disease ,Uterine Cervical Dysplasia ,United States ,Natural history ,medicine.anatomical_structure ,Practice Guidelines as Topic ,Female ,business - Abstract
Although cervical cytology screening programs have dramatically decreased rates of invasive cancer in developed countries most guidelines in the USA were overaggressive in their management of abnormal cytology in adolescents and young women. These management strategies resulted in costly over-treatment. The purpose of this article is to review the evidence for the new guidelines in cytology screening in youth. Natural history studies of human papillomavirus (the cause of abnormal cytology and cervical cancer) suggest there is little risk of a significant pre-cancerous lesion going undetected within the first 3–5 years after the onset of sexual activity. The American Cancer Society now recommends that screening be initiated within 3 years of the onset of vaginal intercourse but no later than 21 years of age. The American Society for Colposcopy and Cervical Pathology allows for follow-up of low-grade squamous intra-epithelial lesions with repeat cytology or human papillomavirus DNA testing rather than immediate referral to colposcopy. The new recommendations appear to be safe and will decrease the current over-referral and over-treatment of adolescents and young women with HPV infections. (authors)
- Published
- 2006
33. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer
- Author
-
Carolyn D. Runowicz, Debbie Saslow, Harmon J. Eyre, Anna-Barbara Moscicki, Robert A. Smith, Carmel J. Cohen, and Diane Solomon
- Subjects
Adult ,Oncology ,Pathology ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,MEDLINE ,Uterine Cervical Neoplasms ,Early detection ,Cytology ,Internal medicine ,medicine ,Humans ,Mass Screening ,Papillomaviridae ,Aged ,Gynecology ,Hysterectomy ,business.industry ,Obstetrics and Gynecology ,Cancer ,Hematology ,General Medicine ,Guideline ,Middle Aged ,Uterine Cervical Dysplasia ,medicine.disease ,United States ,Hpv testing ,DNA, Viral ,Female ,business - Abstract
An update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical neoplasia and cancer, based on recommendations from a formal review and recent workshop, is presented. The new screening recommendations address when to begin screening, when screening may be discontinued, whether to screen women who have had a hysterectomy, appropriate screening intervals, and new screening technologies, including liquid-based cytology and HPV DNA testing.
- Published
- 2003
34. Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents
- Author
-
Yong Ma, Jolene Houser, Stephen J. Durako, Debra A. Murphy, Sepideh Farhat, Craig M. Wilson, Teresa M. Darragh, and Anna-Barbara Moscicki
- Subjects
Male ,Safe Sex ,medicine.medical_specialty ,Adolescent ,Immunology ,Population ,Cohort Studies ,Acquired immunodeficiency syndrome (AIDS) ,Risk Factors ,Cytology ,Prevalence ,medicine ,Humans ,Immunology and Allergy ,Sex Distribution ,Risk factor ,Sida ,education ,Anus Diseases ,education.field_of_study ,AIDS-Related Opportunistic Infections ,biology ,business.industry ,Obstetrics ,Papillomavirus Infections ,HPV infection ,virus diseases ,Odds ratio ,Anus ,medicine.disease ,biology.organism_classification ,United States ,Tumor Virus Infections ,Sexual Partners ,Infectious Diseases ,medicine.anatomical_structure ,Multivariate Analysis ,Female ,business - Abstract
Objective: To examine the prevalence of and risk for anal human papillomavirus (HPV) infection and abnormal anal cytology in sexually active adolescents. Design: Prevalence data from adolescents aged 13–18 years with and without HIV infection and with a history of high-risk sexual behavior. Methods: HPV DNA was detected using amplification techniques. Abnormal anal cytology was defined as atypical squamous cell of undetermined significance or worse. Results: Prevalence of anal HPV infection was similar in HIV-infected [28/58 (48%)] and uninfected [9/25 (36%)] boys (P = 0.3) but greater in HIV-infected [59/183 (59%)] than in uninfected [11/82 (13%)] girls (P < 0.001). Perianal warts were a risk for anal HPV in both boys [odds ratio (OR) 15.5; 95% confidence interval (CI) 1.6–149] and girls (OR 9.9; 95% CI 1.9–51.3). In subjects without anal warts HIV infection was significant for girls (OR 2.3; 95% CI 1.1–4.9) and homosexual/bisexual orientation was significant for boys (OR 5.2; 95% CI 1.3–20.6). Abnormal anal cytology was more common among boys [32/77 (41.6%)] than girls [38/230 (16.5%)] (P
- Published
- 2003
35. Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents
- Author
-
Sten H. Vermund, Craig M. Wilson, Christie A. Holland, Bret J. Rudy, Anna-Barbara Moscicki, Larry R. Muenz, Peggy A. Crowley-Nowick, and Steven D. Douglas
- Subjects
medicine.medical_specialty ,education.field_of_study ,biology ,business.industry ,Immunology ,Population ,virus diseases ,biology.organism_classification ,medicine.disease ,Adolescent medicine ,Infectious Diseases ,Clinical research ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,Cohort ,medicine ,Immunology and Allergy ,Viral disease ,Risk factor ,Sida ,business ,education - Abstract
The objective was to examine potential hematologic and immunologic markers for healthy adolescents and for adolescents infected with HIV. The REACH Project (Reaching for Excellence in Adolescent Care and Health) of the Adolescent Medicine HIV/AIDS Research Network (AMHARN) recruits HIV-infected and high-risk HIV-uninfected adolescents aged at least 13 but less than 19 years. The study evaluates biomedical and behavioral features of HIV infection as observed while under medical care for HIV infection and adolescent health. Blood samples were collected from HIV-infected and HIV-uninfected subjects at 16 clinical sites. Cell phenotypes were determined using standard single dual or three-color flow cytometry. This report includes data at enrollment for 94 HIV-positive adolescents who had never received antiretroviral therapy (ART) (mean age 17.4 ± 1.0 years for males and 16.5 ± 1.3 years for females) and 149 HIV-negative adolescents (mean age 16.7 ± 1.2 years for males and 16.6 ± 1.2 years for females); this is the antiretroviral therapy-naive subset drawn from 294 HIV-positive and 149 HIV-negative adolescents enrolled in the REACH Cohort. The total leukocyte count was significantly reduced in the HIV-positive females in comparison with the HIV-negative females (P < 0.001). There was a reduction in natural killer cells (P < 0.05) in HIV-positive females (mean 140.6 ± 104.2 x 10/6 cells/l) in comparison with HIV-negative females (184.3 ± 142.5 x 10/6 cells/l) whereas no differences were found between the two groups of males. The reduction in the total CD4 cell count in HIV-positive males and females in comparison with the HIV-negative subjects was the consequence of a decrease in both the naive CD4 and memory CD4 components. There was a striking increase in the mean number of CD8 memory cells in HIV-positive compared with HIV-negative adolescents and a corresponding increase in the percentage of these cells. In contrast naive CD8 cells were present in increased numbers but their percentage was decreased. These studies of adolescents provide normative data for high-risk healthy adolescents as well as baseline immunologic data for a cohort of ART-naive HIV-positive adolescents. This comparison suggests that this untreated recently infected group had relatively intact immunologic parameters. (authors)
- Published
- 1999
36. Oral Human Papillomavirus in Youth From the Pediatric HIV/AIDS Cohort Study
- Author
-
Moscicki, Anna-Barbara, primary, Farhat, Sepideh, additional, Yao, Tzy-Jyun, additional, Ryder, Mark I., additional, Russell, Jonathan S., additional, Van Dyke, Russell B., additional, Hazra, Rohan, additional, and Shiboski, Caroline H., additional
- Published
- 2016
- Full Text
- View/download PDF
37. Variability of Human Papillomavirus DNA Testing in a Longitudinal Cohort of Young Women
- Author
-
Stephen Siboshski, Joel M. Palefsky, Anna-Barbara Moscicki, Gregory D. Smith, and Gary K. Schoolnik
- Subjects
Gynecology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Hybridization probe ,Obstetrics and Gynecology ,Physiology ,Dot blot ,medicine.disease ,law.invention ,Nucleic acid thermodynamics ,medicine.anatomical_structure ,Dysplasia ,law ,Cytology ,Biopsy ,Medicine ,business ,Cervix ,Polymerase chain reaction - Abstract
OBJECTIVE To determine the variability in human papillomavirus (HPV) DNA testing of the cervix in young women found positive for HPV DNA by dot blot hybridization on routine examination. METHODS Young women who were found to be HPV DNA-positive on routine screening using an RNA-DNA dot blot hybridization method were asked to return for repeat HPV DNA sampling, cytology, colposcopic examination, and biopsy if indicated. Those who had no histologic evidence of cervical dysplasia were asked to return every 4 months for cytology and HPV DNA testing using standardized RNA-DNA hybridization and polymerase chain reaction techniques. RESULTS The women were followed for a mean of 27.6 months (range 13-40) with a mean of six visits (range four to ten). One-third of the women remained consistently or intermittently HPV DNA-positive by RNA-DNA dot blot hybridization, and almost 50% of the women remained consistently or intermittently positive using polymerase chain reaction techniques. Women were more likely to be positive by polymerase chain reaction than by RNA-DNA hybridization at both 1 year and after 2 years of follow-up (P < .05). However, rates for persistent positive tests by either method were similar at 1 and 2 years of follow-up. Forty percent of the subjects had new or different types than the original HPV type appear during follow-up. All five women who had evidence of spontaneous regression of cytologic abnormalities became HPV DNA-negative by both methods. CONCLUSIONS Our data suggest that a portion of women infected with HPV appear to eliminate the infection over a relatively short period and are at low or no risk of developing disease. Persistent DNA negativity was also found in those women undergoing spontaneous regression. However, a substantial proportion of women remained intermittently positive by RNA-DNA hybridization and polymerase chain reaction. This finding suggests that the virus remains latent in some individuals and may undergo reactivation, defined by sufficient replication to allow detection by means less sensitive than polymerase chain reaction.
- Published
- 1993
38. Screening for Anal Cancer in Women
- Author
-
Moscicki, Anna-Barbara, primary, Darragh, Teresa M., additional, Berry-Lawhorn, J. Michael, additional, Roberts, Jennifer M., additional, Khan, Michelle J., additional, Boardman, Lori A., additional, Chiao, Elizabeth, additional, Einstein, Mark H., additional, Goldstone, Stephen E., additional, Jay, Naomi, additional, Likes, Wendy M., additional, Stier, Elizabeth A., additional, Welton, Mark L., additional, Wiley, Dorothy J., additional, and Palefsky, Joel M., additional
- Published
- 2015
- Full Text
- View/download PDF
39. Biological and Behavioral Risks for Incident Chlamydia trachomatis Infection in a Prospective Cohort
- Author
-
Hwang, Loris Y., primary, Ma, Yifei, additional, and Moscicki, Anna-Barbara, additional
- Published
- 2014
- Full Text
- View/download PDF
40. Pressure Ulcer Treatment in Pediatric Patients
- Author
-
Schlüer, Anna-Barbara, primary, Schols, Jos M. G. A., additional, and Halfens, Ruud J. G., additional
- Published
- 2013
- Full Text
- View/download PDF
41. Clinical Question
- Author
-
Anna-Barbara Moscicki
- Subjects
Medical education ,business.industry ,Clinical question ,Ask price ,Obstetrics and Gynecology ,Medicine ,General Medicine ,business - Published
- 2008
42. Clinical Question
- Author
-
Mary Rubin, Cox J, Leo B. Twiggs, Mark Spitzer, Anna-Barbara Moscicki, Kaufman Rh, and Diem K
- Subjects
Gynecology ,Colposcopy ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Obstetrics and Gynecology ,General Medicine ,medicine.disease ,Cervical intraepithelial neoplasia ,Squamous intraepithelial lesion ,Uterine Cervical Dysplasia ,Metaplasia ,medicine ,Differential diagnosis ,medicine.symptom ,business - Published
- 2008
43. Response to Letters Regarding Article, “Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic, Trypanosoma cruzi –Seropositive Former Blood Donors”
- Author
-
Sabino, Ester C., primary, Ribeiro, Antonio L., additional, Salemi, Vera M.C., additional, Ianni, Barbara M., additional, Nastari, Luciano, additional, Fernandes, Fabio, additional, Di Lorenzo Oliveira, Claudia, additional, Antunes, Andre P., additional, Menezes, Marcia M., additional, Patavino, Giuseppina M., additional, Capuani, Ligia, additional, de Almeida-Neto, Cesar, additional, Sachdev, Vandana, additional, Carrick, Danielle M., additional, Wright, David, additional, Kavounis, Katherine, additional, Gonzalez, Thelma T., additional, Custer, Brian, additional, Busch, Michael P., additional, Murphy, Edward L., additional, and Carneiro-Proietti, Anna-Barbara, additional
- Published
- 2013
- Full Text
- View/download PDF
44. Ten-Year Incidence of Chagas Cardiomyopathy Among Asymptomatic Trypanosoma cruzi –Seropositive Former Blood Donors
- Author
-
Sabino, Ester C., primary, Ribeiro, Antonio L., additional, Salemi, Vera M.C., additional, Di Lorenzo Oliveira, Claudia, additional, Antunes, Andre P., additional, Menezes, Marcia M., additional, Ianni, Barbara M., additional, Nastari, Luciano, additional, Fernandes, Fabio, additional, Patavino, Giuseppina M., additional, Sachdev, Vandana, additional, Capuani, Ligia, additional, de Almeida-Neto, Cesar, additional, Carrick, Danielle M., additional, Wright, David, additional, Kavounis, Katherine, additional, Goncalez, Thelma T., additional, Carneiro-Proietti, Anna Barbara, additional, Custer, Brian, additional, Busch, Michael P., additional, and Murphy, Edward L., additional
- Published
- 2013
- Full Text
- View/download PDF
45. Revised Terminology for Cervical Histopathology and Its Implications for Management of High-Grade Squamous Intraepithelial Lesions of the Cervix
- Author
-
Waxman, Alan G., primary, Chelmow, David, additional, Darragh, Teresa M., additional, Lawson, Herschel, additional, and Moscicki, Anna-Barbara, additional
- Published
- 2012
- Full Text
- View/download PDF
46. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
- Author
-
Saslow, Debbie, primary, Solomon, Diane, additional, Lawson, Herschel W., additional, Killackey, Maureen, additional, Kulasingam, Shalini L., additional, Cain, Joanna M., additional, Garcia, Francisco A. R., additional, Moriarty, Ann T., additional, Waxman, Alan G., additional, Wilbur, David C., additional, Wentzensen, Nicolas, additional, Downs, Levi S., additional, Spitzer, Mark, additional, Moscicki, Anna-Barbara, additional, Franco, Eduardo L., additional, Stoler, Mark H., additional, Schiffman, Mark, additional, Castle, Philip E., additional, and Myers, Evan R., additional
- Published
- 2012
- Full Text
- View/download PDF
47. Cervical Ectopy and the Acquisition of Human Papillomavirus in Adolescents and Young Women
- Author
-
Hwang, Loris Y., primary, Lieberman, Jay A., additional, Ma, Yifei, additional, Farhat, Sepideh, additional, and Moscicki, Anna-Barbara, additional
- Published
- 2012
- Full Text
- View/download PDF
48. Measurement of Mucosal Biomarkers in a Phase 1 Trial of Intravaginal 3% StarPharma LTD 7013 Gel (VivaGel) to Assess Expanded Safety
- Author
-
Moscicki, Anna-Barbara, primary, Kaul, Rupert, additional, Ma, Yifei, additional, Scott, Mark E., additional, Daud, Ibrahim I., additional, Bukusi, Elizabeth A., additional, Shiboski, Stephen, additional, Rebbapragada, Anuradha, additional, Huibner, Sanja, additional, and Cohen, Craig R., additional
- Published
- 2012
- Full Text
- View/download PDF
49. Human Papillomavirus in Men
- Author
-
Moscicki, Anna-Barbara, primary and Palefsky, Joel M., additional
- Published
- 2011
- Full Text
- View/download PDF
50. Rate of and Risks for Regression of Cervical Intraepithelial Neoplasia 2 in Adolescents and Young Women
- Author
-
Moscicki, Anna-Barbara, primary, Ma, Yifei, additional, Wibbelsman, Charles, additional, Darragh, Teresa M., additional, Powers, Adaleen, additional, Farhat, Sepideh, additional, and Shiboski, Stephen, additional
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.